A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8(+) T cell responses

PD-1 and CTLA-4 antibodies offer great hope for cancer immunotherapy. However, many patients are incapable of responding to PD-1 and CTLA-4 blockade and show low response rates due to insufficient immune activation. The combination of checkpoint blockers has been proposed to increase the response ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Wenjie, Zhou, Xiuman, Wang, Hongfei, Li, Wanqiong, Chen, Guanyu, Sui, Xinghua, Li, Guodong, Qi, Yuanming, Gao, Yanfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332792/
https://www.ncbi.nlm.nih.gov/pubmed/32642411
http://dx.doi.org/10.1016/j.apsb.2020.01.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332792/
https://www.ncbi.nlm.nih.gov/pubmed/32642411
http://dx.doi.org/10.1016/j.apsb.2020.01.005

Ejemplares similares